Cellular immunotherapy of cancer
The field of immunotherapy is currently one of the most promising developments in medical science now helping thousands of patients with cancer or autoimmune diseases. At KIA we have recently established a group engaging in the development of new ways to make the patient’s T cells capable of killing cancer cells and curing the patient. We use the chimeric antigen-receptor T cells (CAR T cells) method. The group works in close collaboration with the Morten Gjerstorff group at IMM, SDU, and with professor Niels Abildgaard at the Dept. of Hematology, OUH. with one of the strongest groups in the field: the Marcela V. Maus group at Massachusetts’ General Hospital and Harvard University. Dr. Maus is adjunct professor at KIA.
Professor Torben Barington
Clinical Immunology, SDU
Klinisk Immunologisk afd.
J. B. Winsløws Vej 4, 5000 Odense
Members of the team
Maria Ormhøj, PhD student
Mike Barnkob, MD, research associate
Kristina Fruerlund Rasmussen, MD, research associate
Development of Chimeric Antigen Receptor T cells Targeting the B-cell Receptor Signaling Pathway.
Forbedring af effektiviteten af CAR T-celler dannet ud fra blodceller fra patienter med blodkræft.